PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 Read more
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy Read more
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication Read more
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer Read more
Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a first-in-class agent in dermatology Read more
VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence Read more
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines Read more
Ipsen’s Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA Read more